Oncology

Bariatric Surgery Impact on Cancer Screening (BASICS)

Posted on by Jodi Snare

Study Updated 03/05/2024

Study Design: Retrospective Observational
PCORnet Infrastructure: Collaboration, CDM, Engagement
Principal Investigator: Kathleen McTigue
Site Name: University of Pittsburgh/UPMC
PCORnet® Network Partner: PaTH
Funder: NIH/NCI
Funding Date: 2023
Study Duration: 2023 – 2024
Participating Clinical Research Networks: GPC, PaTH, STAR
Therapeutic Area: Oncology
Condition: Obesity
Population: Adults with BMI 35+ who have had bariatric procedures
Status: Active, not recruiting

Research Question(s):

  1. How are patients’ cancer screening practices impacted by bariatric surgery for weight loss?

Neuroendocrine Tumors – Patient Reported Outcomes (NET-PRO)

Posted on by Jodi Snare

Study Updated 03/25/2024

ClinicalTrials.gov#: NCT05064150
Study Design: Prospective Observational
PCORnet Infrastructure: Collaboration, CDM, Engagement, Single IRB
Principal Investigator: Michael O’Rorke
Site Name: University of Iowa
PCORnet® Network Partner: GPC
Funder: Patient-Centered Outcomes Research Institute (PCORI), project website
Funding Date: 2021
Study Duration: 2021 – 2024
Participating Clinical Research Networks: GPC, OneFlorida+, PaTH, STAR
Therapeutic Area: Oncology
Condition: Neuroendocrine Tumors; Gastroenteropancreatic Neuroendocrine Tumor; Lung Neuroendocrine Neoplasm; Neuroendocrine Carcinoma
Population: 18 Years and older (Adult, Older Adult)
Status: Enrolling by Invitation

Research Question(s):

Which care options work, for whom, and under which circumstances in order to improve symptom management, treatment outcomes and quality of life among NET patients?

  • Common treatment combinations and their relation to disease symptoms and quality of life
  • Identification of the best ordering of treatments and relation to patient outcomes and survival
  • The impact of patient traits and tumor characteristics on treatment choice(s) and survival

Outcomes Database to Prospectively Assess Changing Therapy Landscape in Renal Cell Carcinoma (ODYSSEY RCC)

Posted on by Jodi Snare

Study Updated 03/28/2024

ClinicalTrials.gov#: NCT04919122
Study Design: Prospective Observational
PCORnet Infrastructure: Collaboration, CDM (+supplemental data), Engagement
Principal Investigator: Dan George
Site Name: Duke Clinical Research Institute
PCORnet® Network Partner: Coordinating Center
Funder: Exelixis, Bristol Myers Squibb, Merck, Pfizer
Funding Date: 2020
Study Duration: 2022 – 2026
Participating Clinical Research Networks: GPC, PaTH, REACHnet, STAR
Therapeutic Area: Oncology
Condition: Metastatic Renal Cell Carcinoma
Population: 19 Years and older (Adult, Older Adult)
Status: Recruiting

Research Question(s):

Can a research registry of patients with metastatic renal cell carcinoma (mRCC) patients help us better understand cancer management and health-related quality of life while receiving mRCC specific treatment? In combination with patient and physician surveys, PCORnet will be used to help us answer these questions.